Page 13 - HSP-Assure Test Info Booklet Direct Final 12_2020

Page 2 – Frank Lou, Representing Assure Tech. (Hangzhou) Co., Ltd.

On August 16, 2020, you requested to revise the Scope of Authorization to add a new indication
for use. Based on that request, and having concluded that revising the July 6, 2020, EUA is
appropriate to protect the public health or safety under section 564(g)(2)(C) of the Act (21
U.S.C. § 360bbb-3(g)(2)(C)), FDA is reissuing the July 6, 2020, letter in its entirety with the
4
revisions incorporated. Accordingly, your product is hereby authorized pursuant to section
564 of the Act when used pursuant to the Scope of Authorization (Section II) and Conditions of
Authorization (Section IV) of this reissued letter.

On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the
Department of Health and Human Services (HHS) determined that there is a public health
emergency that has a significant potential to affect national security or the health and security of
United States citizens living abroad, and that involves the virus that causes COVID-19.
Pursuant to Section 564 of the Act, and on the basis of such determination, the Secretary of
HHS then declared that circumstances exist justifying the authorization of emergency use of in
vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 subject to the
terms of any authorization issued under Section 564(a) of the Act. 5

FDA considered the totality of scientific information available in authorizing the emergency use
of your product for the indication above. A summary of the performance information FDA
relied upon is contained in the Instructions for Use (identified below).

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the
Act are met, I am authorizing the emergency use of your product, described in the Scope of
Authorization of this letter (Section II), subject to the terms of this authorization.

I. Criteria for Issuance of Authorization

I have concluded that the emergency use of your product meets the criteria for issuance of an
authorization under Section 564(c) of the Act, because I have concluded that:

1. The SARS-CoV-2 can cause a serious or life-threatening disease or condition,
including severe respiratory illness, to humans infected by this virus;

2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe
that your product may be effective in diagnosing recent or prior infection with SARS-
CoV-2 by identifying individuals with an adaptive immune response to the virus that
causes COVID-19, and that the known and potential benefits of your product when used
for such use, outweigh the known and potential risks of your product; and

Your product was intended for use as an aid in identifying individuals with an adaptive immune response to SARS-
CoV-2, indicating recent or prior infection. Testing was limited to laboratories certified under the Clinical
Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet requirements to perform
moderate or high complexity tests.
4 The revisions to the July 6, 2020, letter include: 1) addition of fingerstick specimen type, 2) addition of POC
laboratories as authorized laboratories, and 3) conforming updates to the authorized labeling.
5 U.S. Department of Health and Human Services, Determination of a Public Health Emergency and Declaration
that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the Federal Food, Drug, and
Cosmetic Act, 21 U.S.C. § 360bbb-3. 85 FR 7316 (February 7, 2020).